Development of a prognostic scoring system for chronic myeloid
leukemia in blast phase

J 2026

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

LAUSEKER, Michael; Tomasz SACHA; Hana KLAMOVA; Julia YAKOLEVA; Elza LOMAIA et al.

Základní údaje

Originální název

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

Autoři

LAUSEKER, Michael; Tomasz SACHA; Hana KLAMOVA; Julia YAKOLEVA; Elza LOMAIA; Dragana MILOJKOVIC; Christian FABISCH; Franck E NICOLINI; Ulla OLSSON-STROMBERG; Daniela ŽÁČKOVÁ; Krzysztof LEWANDOWSKI; Philipp ERNST; Fausto CASTAGNETTI; Klaus HIRSCHBUHL; Irena ZUPAN; Astghik VOSKANYAN; Aleksandra GOLOS; Jochen J FRIETSCH; Justyna GIL; Edgar FABER; Stefan W KRAUSE; Anne PARRY; Susanne SAUSSELE; Sonja HEIBL; Georg-Nikolaus FRANKE; Luis Felipe CASADO; Edyta PACZKOWSKA; Holger HEBART; Matthias EDER; Peter ANHUT; Karolin TRAUTMANN-GRILL; Elzbieta SZCZEPANEK; Thomas SUDHOFF; Elzbieta PATKOWSKA; Alexander KIANI; Thomas ERNST; Jane APPERLEY; Jiri MAYER; Andreas HOCHHAUS; Markus PFIRRMANN a Annamaria BRIOLI

Vydání

Leukemia, LONDON, SPRINGERNATURE, 2026, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 13.400 v roce 2024

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 4. 2026 12:56, Mgr. Tereza Miškechová

Anotace

V originále

Currently there is no established prognostic scoring system for patients with chronic myeloid leukemia (CML) in blast phase (BP). This study aimed to identify prognostic factors of CML-BP in a large cohort of prospectively and retrospectively collected patients and to develop a readily available prognostic scoring system at the onset of BP to enable future comparison between different trials and series. The analyses were based on 275 patients from thirteen countries, collected within the European LeukemiaNet Blast Phase Registry with a median observation time of 45 months and a median OS of 18.9 months. A Cox proportional hazards model for overall survival (OS) was employed, missing values were imputed. The study identified six independent prognostic factors: blast percentage, platelet count, age (all at onset of CML-BP), immunophenotype of BP, extramedullary disease, and previous history of CML. The low-risk group, encompassing 14% of patients, had a median OS of 97 months, the intermediate-risk group (59% of patients) of 22 months, and the high-risk group (27% of patients) of 9 months. Cross-validation demonstrated a good performance of the score, although external validation is strongly recommended. Despite the inherent limitations of registry data, the findings offer robust insights into prognostic factors for CML-BP.

Citovat

@article{2565347,
   author = {Lauseker, Michael and Sacha, Tomasz and Klamova, Hana and Yakoleva, Julia and Lomaia, Elza and Milojkovic, Dragana and Fabisch, Christian and Nicolini, Franck E and OlssonandStromberg, Ulla and Žáčková, Daniela and Lewandowski, Krzysztof and Ernst, Philipp and Castagnetti, Fausto and Hirschbuhl, Klaus and Zupan, Irena and Voskanyan, Astghik and Golos, Aleksandra and Frietsch, Jochen J and Gil, Justyna and Faber, Edgar and Krause, Stefan W and Parry, Anne and Saussele, Susanne and Heibl, Sonja and Franke, GeorgandNikolaus and Casado, Luis Felipe and Paczkowska, Edyta and Hebart, Holger and Eder, Matthias and Anhut, Peter and TrautmannandGrill, Karolin and Szczepanek, Elzbieta and Sudhoff, Thomas and Patkowska, Elzbieta and Kiani, Alexander and Ernst, Thomas and Apperley, Jane and Mayer, Jiri and Hochhaus, Andreas and Pfirrmann, Markus and Brioli, Annamaria},
   article_location = {LONDON},
   doi = {https://doi.org/10.1038/s41375-026-02875-9},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Development of a prognostic scoring system for chronic myeloid leukemia in blast phase},
   url = {https://www.nature.com/articles/s41375-026-02875-9},
   year = {2026}
}

TY  - JOUR
ID  - 2565347
AU  - Lauseker, Michael - Sacha, Tomasz - Klamova, Hana - Yakoleva, Julia - Lomaia, Elza - Milojkovic, Dragana - Fabisch, Christian - Nicolini, Franck E - Olsson-Stromberg, Ulla - Žáčková, Daniela - Lewandowski, Krzysztof - Ernst, Philipp - Castagnetti, Fausto - Hirschbuhl, Klaus - Zupan, Irena - Voskanyan, Astghik - Golos, Aleksandra - Frietsch, Jochen J - Gil, Justyna - Faber, Edgar - Krause, Stefan W - Parry, Anne - Saussele, Susanne - Heibl, Sonja - Franke, Georg-Nikolaus - Casado, Luis Felipe - Paczkowska, Edyta - Hebart, Holger - Eder, Matthias - Anhut, Peter - Trautmann-Grill, Karolin - Szczepanek, Elzbieta - Sudhoff, Thomas - Patkowska, Elzbieta - Kiani, Alexander - Ernst, Thomas - Apperley, Jane - Mayer, Jiri - Hochhaus, Andreas - Pfirrmann, Markus - Brioli, Annamaria
PY  - 2026
TI  - Development of a prognostic scoring system for chronic myeloid leukemia in blast phase
JF  - Leukemia
PB  - SPRINGERNATURE
SN  - 08876924
UR  - https://www.nature.com/articles/s41375-026-02875-9
N2  - Currently there is no established prognostic scoring system for patients with chronic myeloid leukemia (CML) in blast phase (BP). This study aimed to identify prognostic factors of CML-BP in a large cohort of prospectively and retrospectively collected patients and to develop a readily available prognostic scoring system at the onset of BP to enable future comparison between different trials and series. The analyses were based on 275 patients from thirteen countries, collected within the European LeukemiaNet Blast Phase Registry with a median observation time of 45 months and a median OS of 18.9 months. A Cox proportional hazards model for overall survival (OS) was employed, missing values were imputed. The study identified six independent prognostic factors: blast percentage, platelet count, age (all at onset of CML-BP), immunophenotype of BP, extramedullary disease, and previous history of CML. The low-risk group, encompassing 14% of patients, had a median OS of 97 months, the intermediate-risk group (59% of patients) of 22 months, and the high-risk group (27% of patients) of 9 months. Cross-validation demonstrated a good performance of the score, although external validation is strongly recommended. Despite the inherent limitations of registry data, the findings offer robust insights into prognostic factors for CML-BP.
ER  -

Přehled o publikaci